Volume 25, Number 7—July 2019
Added Value of Comprehensive Program to Provide Universal Access to Care for Sputum Smear–Negative Drug-Resistant Tuberculosis, China
||Light microscopy (Ziehl–Neelsen staining), smear examination, and chest radiograph for all presumptive TB patients
||LED fluorescence microscopy (auramine staining), smear examination, and chest radiograph for all presumptive TB patients; culture for all patients with a diagnosis of smear-negative TB
|City||Culture and phenotypic DST only for patients at high risk for MDR TB; culture for smear-positive patients in Zhenjiang||Line-probe assay (Genechip; CapitaBio, http://www.capitalbiotech.com) used in Yichang; GenoType (Hain Lifesciences, https://www.hain-lifescience.de/ en/company/contact.html) used in Zhenjiang for all bacteriologically confirmed pulmonary TB|
*DST, drug susceptibility testing; LED, light-emitted diode; MDR TB, multidrug-resistant tuberculosis; TB, tuberculosis.
Page created: June 17, 2019
Page updated: June 17, 2019
Page reviewed: June 17, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.